Author: CNS Pharmaceuticals, Inc.

Posted Date:

May 4, 2026

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

CNS Pharmaceuticals, Inc.

May 4, 2026
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

CNS Pharmaceuticals, Inc.

March 11, 2026
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team

CNS Pharmaceuticals, Inc.

March 2, 2026
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company’s Recently Initiated Strategic Transformation

CNS Pharmaceuticals, Inc.

February 17, 2026
CNS Pharmaceuticals Issues Letter to Shareholders

CNS Pharmaceuticals, Inc.

January 28, 2026